Homologous recombination in human iPS and ES cells for use in gene correction therapy

  • Nakayama M
  • 56

    Readers

    Mendeley users who have this article in their library.
  • 9

    Citations

    Citations of this article.

Abstract

The emergence of induced pluripotent stem (iPS) cell technology has shifted gene correction therapy toward reality. Crucial issues are ensuring the safety of using iPS cell technology in patients and discovering how best to transfer genetically manipulated iPS cells back into patients. One key issue that has hindered progress of gene correction therapy, however, is the inability to achieve efficient homologous recombination in human iPS cells. This review focuses on recently developed technologies that aim to improve homologous recombination in human embryonic stem cells and on their application to iPS cells. ?? 2010 Elsevier Ltd. All rights reserved.

Get free article suggestions today

Mendeley saves you time finding and organizing research

Sign up here
Already have an account ?Sign in

Find this document

Get full text

Authors

  • Manabu Nakayama

Cite this document

Choose a citation style from the tabs below

Save time finding and organizing research with Mendeley

Sign up for free